A retrospective prognostic evaluation using unsupervised learning in the treatment of COVID-19 patients with hypertension treated with ACEI/ARB drugs

被引:1
|
作者
Ge, Liye [1 ]
Meng, Yongjun [1 ]
Ma, Weina [1 ]
Mu, Junyu [2 ]
机构
[1] Shanghai Univ Med & Hlth Sci, Jiading Dist Cent Hosp Affiliated, Shanghai, Peoples R China
[2] Nanjing Med Univ, Nanjing, Peoples R China
来源
PEERJ | 2024年 / 12卷
关键词
Unsupervised learning; Prognostic evaluation; ACEI; ARB; COVID-19; Hypertension; MANAGEMENT; DISEASE;
D O I
10.7717/peerj.17340
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction. This study aimed to evaluate the prognosis of patients with COVID19 and hypertension who were treated with angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor B (ARB) drugs and to identify key features affecting patient prognosis using an unsupervised learning method. Methods. A large-scale clinical dataset, including patient information, medical history, and laboratory test results, was collected. Two hundred patients with COVID-19 and hypertension were included. After cluster analysis, patients were divided into good and poor prognosis groups. The unsupervised learning method was used to evaluate clinical characteristics and prognosis, and patients were divided into different prognosis groups. The improved wild dog optimization algorithm (IDOA) was used for feature selection and cluster analysis, followed by the IDOA-k-means algorithm. The impact of ACEI/ARB drugs on patient prognosis and key characteristics affecting patient prognosis were also analysed. Results. Key features related to prognosis included baseline information and laboratory test results, while clinical symptoms and imaging results had low predictive power. The top six important features were age, hypertension grade, MuLBSTA, ACEI/ARB, NTproBNP, and high-sensitivity troponin I. These features were consistent with the results of the unsupervised prediction model. A visualization system was developed based on these key features. Conclusion. Using unsupervised learning and the improved k-means algorithm, this study accurately analysed the prognosis of patients with COVID-19 and hypertension. The use of ACEI/ARB drugs was found to be a protective factor for poor clinical prognosis. Unsupervised learning methods can be used to differentiate patient populations and assess treatment effects. This study identified important features affecting patient prognosis and developed a visualization system with clinical significance for prognosis assessment and treatment decision-making.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
    Li, Gang
    Hu, Rui
    Zhang, Xuejiao
    HYPERTENSION RESEARCH, 2020, 43 (06) : 588 - 590
  • [2] Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
    Gang Li
    Rui Hu
    Xuejiao Zhang
    Hypertension Research, 2020, 43 : 588 - 590
  • [3] Continuation of ACEI/ARB treatment in patients diagnosed with COVID-19
    Avila Cabreja, Jose Alejandro
    Garcia Mendez, Felicia Maria
    Sosa Gonzalez, Ismael
    Zayas Fundora, Emmanuel
    ATENCION PRIMARIA, 2021, 53 (06):
  • [4] ACEi/ARB and Deaths of COVID-19 Patients
    Azad, Gulam Navi
    Kumar, Anoop
    CURRENT HYPERTENSION REVIEWS, 2022, 18 (02) : 158 - 162
  • [5] Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19
    Xiang, Dong
    Ren, Xiuhua
    Chen, Qian
    Yu, Hengyi
    Li, Xiping
    Liu, Dong
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2021, 43 (04) : 305 - 310
  • [6] Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
    Ma, Jing
    Shi, Xiaowei
    Yu, Jiong
    Lv, Feifei
    Wu, Jian
    Sheng, Xinyu
    Pan, Qiaoling
    Yang, Jinfeng
    Cao, Hongcui
    Li, Lanjuan
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [7] ARB might be superior to ACEI for treatment of hypertensive COVID-19 patients
    Zhao, Hong-Jin
    Li, Yan
    Wang, De-Yu
    Yuan, Hai-Tao
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (23) : 11031 - 11034
  • [8] Safety of ACEi and ARB in COVID-19 management: A retrospective analysis
    Kumar, Sabina
    Nikravesh, Mastaneh
    Chukwuemeka, Umeh
    Randazzo, Michael
    Flores, Peter
    Choday, Prithi
    Raja, Ajith
    Aseri, Mahendra
    Shivang, Shah
    Chaudhuri, Sumanta
    Barve, Pranav
    CLINICAL CARDIOLOGY, 2022, 45 (07) : 759 - 766
  • [9] COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome
    Hu, Jianhua
    Zhang, Xiaoli
    Zhang, Xuan
    Zhao, Hong
    Lian, Jiangshan
    Hao, Shaorui
    Jia, Hongyu
    Yang, Meifang
    Lu, Yingfeng
    Xiang, Dairong
    Cai, Huan
    Zhang, Shanyan
    Gu, Jueqing
    Ye, Chanyuan
    Yu, Guodong
    Jin, Ciliang
    Zheng, Lin
    Yang, Yida
    Sheng, Jifang
    JOURNAL OF INFECTION, 2020, 81 (06) : 983 - 986
  • [10] Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
    Rico-Mesa, Juan Simon
    White, Averi
    Anderson, Allen S.
    CURRENT CARDIOLOGY REPORTS, 2020, 22 (05)